Neovasc (NASDAQ:NVCN) announces that the German Institute for the Hospital Remuneration System, Institut für das Entgeltsystem im Krankenhaus, has upgraded the status of Reducer from 4 to 1,the highest priority designation available.The new status, valid for one year and renewable annually, enables German hospitals to negotiate reimbursement coverage for Neovasc Reducer therapy under the country's health insurance system.CE-Mark'd Reducer is used to treat refractory angina, a painful condition caused by inadequate blood flow to the heart despite standard revascularization or cardiac drug treatments.
Neovasc's Reducer nabs elevated reimbursement status in Germany seekingalpha.com/news/3327257?source=ansh $NVCN